Last: | $1.02 |
---|---|
Change Percent: | -0.99% |
Open: | $1.02 |
Close: | $1.02 |
High: | $1.02 |
Low: | $0.97 |
Volume: | 57,189 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.02 | $1.02 | $1.02 | $1.02 | $0.97 | 57,189 | 10-12-2022 |
$1.01 | $1.01 | $1.01 | $1.045 | $1.01 | 27,473 | 10-11-2022 |
$1.03 | $1.11 | $1.03 | $1.11 | $1.03 | 12,291 | 10-10-2022 |
$1.06 | $1.14 | $1.06 | $1.14 | $1.06 | 24,824 | 10-07-2022 |
$1.14 | $1.16 | $1.14 | $1.19 | $1.13 | 35,890 | 10-06-2022 |
$1.15 | $1.08 | $1.15 | $1.16 | $1.07 | 36,527 | 10-05-2022 |
$1.04 | $1 | $1.04 | $1.06 | $1 | 66,143 | 10-04-2022 |
$1.0201 | $1 | $1.0201 | $1.05 | $1 | 79,248 | 10-03-2022 |
$0.986 | $1.05 | $0.986 | $1.05 | $0.97 | 75,142 | 09-30-2022 |
$1.06 | $1.06 | $1.06 | $1.06 | $1.04 | 22,936 | 09-29-2022 |
$1.07 | $1.04 | $1.07 | $1.09 | $1.035 | 25,116 | 09-28-2022 |
$1.05 | $1.08 | $1.05 | $1.11 | $1.036 | 40,448 | 09-27-2022 |
$1.04 | $1.04 | $1.04 | $1.06 | $1.03 | 40,177 | 09-26-2022 |
$1.06 | $1.12 | $1.06 | $1.13 | $1.05 | 33,145 | 09-23-2022 |
$1.11 | $1.11 | $1.11 | $1.15 | $1.0801 | 68,318 | 09-22-2022 |
$1.16 | $1.2 | $1.16 | $1.2 | $1.11 | 114,025 | 09-21-2022 |
$1.21 | $1.28 | $1.21 | $1.29 | $1.2 | 79,697 | 09-20-2022 |
$1.29 | $1.31 | $1.29 | $1.33 | $1.2801 | 31,510 | 09-19-2022 |
$1.34 | $1.34 | $1.34 | $1.3683 | $1.3 | 49,378 | 09-16-2022 |
$1.38 | $1.36 | $1.38 | $1.4 | $1.35 | 57,936 | 09-15-2022 |
News, Short Squeeze, Breakout and More Instantly...
Synthetic Biologics Inc. Company Name:
SYN Stock Symbol:
NYSE Market:
Synthetic Biologics Inc. Website:
ROCKVILLE, Md., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Theriva Biologics, Inc. (NYSE American: TOVX), (“Theriva” or the “Company”) is the new name of Synthetic Biologics, Inc. (NYSE American: SYN). The new name, logo and branding elements were introduced to better ref...
ROCKVILLE, Md., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced the presentation of new data from collaborators at Fund...
- The DSMC has reviewed the safety and pharmacokinetic data from Cohort 1 and recommended that the study may proceed to enroll patients into Cohort 2 - ROCKVILLE, Md., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical...